Stryker (NYSE:SYK) Earns “Outperform” Rating from Svb Leerink

Svb Leerink restated their outperform rating on shares of Stryker (NYSE:SYK) in a research report sent to investors on Wednesday, Zacks.com reports. Svb Leerink also issued estimates for Stryker’s Q2 2019 earnings at $1.94 EPS, Q3 2019 earnings at $1.88 EPS, Q4 2019 earnings at $2.43 EPS and FY2020 earnings at $8.98 EPS.

Several other research analysts have also recently issued reports on the stock. BTIG Research reissued a buy rating on shares of Helius Medical Technologies in a report on Monday, March 18th. Deutsche Bank raised their price target on shares of Texas Instruments from $100.00 to $110.00 and gave the company a hold rating in a research report on Wednesday, April 24th. Canaccord Genuity set a C$16.50 price target on shares of Detour Gold and gave the company a buy rating in a research report on Wednesday, April 24th. Zacks Investment Research upgraded shares of HB Fuller from a sell rating to a hold rating in a research report on Tuesday, June 11th. Finally, Cantor Fitzgerald restated a hold rating and set a $68.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Stryker presently has an average rating of Buy and an average target price of $201.41.

Shares of Stryker stock opened at $206.40 on Wednesday. The company has a current ratio of 2.12, a quick ratio of 1.30 and a debt-to-equity ratio of 0.68. The business’s fifty day simple moving average is $197.39. Stryker has a 1 year low of $144.75 and a 1 year high of $210.85. The stock has a market capitalization of $78.00 billion, a PE ratio of 28.24, a PEG ratio of 2.53 and a beta of 0.87.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.84 by $0.04. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the company posted $1.68 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. On average, analysts predict that Stryker will post 8.15 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be given a $0.52 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.08 annualized dividend and a dividend yield of 1.01%. Stryker’s dividend payout ratio (DPR) is 28.45%.

In related news, insider Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $192.40, for a total transaction of $897,738.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Bijoy Sagar sold 2,000 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $190.43, for a total transaction of $380,860.00. Following the transaction, the vice president now owns 3,350 shares in the company, valued at $637,940.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,377 shares of company stock worth $4,081,972. Company insiders own 7.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. ERTS Wealth Advisors LLC acquired a new position in Stryker during the fourth quarter worth about $25,000. Farmers National Bank acquired a new position in Stryker during the first quarter worth about $25,000. Semmax Financial Advisors Inc. purchased a new position in Stryker during the fourth quarter worth about $28,000. Cable Hill Partners LLC purchased a new position in Stryker during the first quarter worth about $30,000. Finally, RPG Investment Advisory LLC raised its stake in Stryker by 160.0% during the first quarter. RPG Investment Advisory LLC now owns 156 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 73.58% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: What is the outlook for the FAANG stocks?

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.